Literature DB >> 12773485

T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells.

Mübeccel Akdis1, Axel Trautmann, Sven Klunker, Isabelle Daigle, Umut C Kucuksezer, Wolfgang Deglmann, Rainer Disch, Kurt Blaser, Cezmi A Akdis.   

Abstract

T cells constitute a large population of cellular infiltrate in atopic/allergic inflammation and a dysregulated, Th2-biased peripheral immune response appears to be an important pathogenetic factor. In atopic dermatitis, circulating cutaneous lymphocyte-associated antigen-bearing (CLA+) CD45RO+ T cells with skin-specific homing property represent an activated memory/effector T cell subset. They express high levels of Fas and Fas ligand and undergo activation-induced apoptosis. The freshly purified CLA+ CD45RO+ T cells of atopic individuals display distinct features of in vivo-triggered apoptosis such as pro-caspase degradation and active caspase-8 formation. In particular, the Th1 compartment of activated memory/effector T cells selectively undergoes activation-induced cell death, skewing the immune response toward surviving Th2 cells in atopic dermatitis patients. The apoptosis of circulating memory/effector T cells was confined to atopic individuals whereas non-atopic patients such as psoriasis, intrinsic-type asthma, contact dermatitis, intrinsic type of atopic dermatitis, bee venom allergic patients, and healthy controls showed no evidence for enhanced T cell apoptosis in vivo. These results define a novel mechanism for peripheral Th2 response in atopic diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773485     DOI: 10.1096/fj.02-1070com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  29 in total

1.  Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model.

Authors:  L Chen; O Martinez; L Overbergh; C Mathieu; B S Prabhakar; L S Chan
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

Review 2.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

3.  Postmortem serum levels of total IgE.

Authors:  Lara Tran; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2016-06-09       Impact factor: 2.686

Review 4.  [Neurodermatitis : Atopy of the skin].

Authors:  R Fölster-Holst
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

5.  Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization.

Authors:  Claudia Traidl-Hoffmann; Valentina Mariani; Hubertus Hochrein; Kathrin Karg; Hermann Wagner; Johannes Ring; Martin J Mueller; Thilo Jakob; Heidrun Behrendt
Journal:  J Exp Med       Date:  2005-02-21       Impact factor: 14.307

Review 6.  Multiple mechanisms of immune suppression by B lymphocytes.

Authors:  Matthew W Klinker; Steven K Lundy
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 7.  T-cell subsets in the pathogenesis of human asthma.

Authors:  Flurina Meiler; Maya Zimmermann; Kurt Blaser; Cezmi A Akdis; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

8.  Different natural killer (NK) receptor expression and immunoglobulin E (IgE) regulation by NK1 and NK2 cells.

Authors:  E Aktas; M Akdis; S Bilgic; R Disch; C S Falk; K Blaser; C Akdis; G Deniz
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 9.  Pathogenesis of allergic airway inflammation.

Authors:  Devendra K Agrawal; Zhifei Shao
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

10.  An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice.

Authors:  Daniel Voskas; Yael Babichev; Ling S Ling; Jennifer Alami; Yuval Shaked; Robert S Kerbel; Brian Ciruna; Daniel J Dumont
Journal:  J Leukoc Biol       Date:  2008-05-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.